← All trials
NCT05976828
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2024
- Primary completion
- Dec 30, 2024
- Completion date
- Aug 14, 2033
- First posted
- Aug 4, 2023
- Last posted
- Sep 28, 2023
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ImmunityBio, Inc.Lead sponsor
- ImmunityBio, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.